Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.

Novartis

Status and phase: Completed; Phase 2

Conditions: Alzheimer Disease

Treatments: Biological: Placebo; Biological: CAD106

Study type: Interventional

Funder types: Industry

Identifiers

NCT00733863

CCAD106A2201

Details and patient eligibility

About

This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with mild Alzheimer's disease.

Enrollment: 27 patients

Sex: All

Ages: 40 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Mild Alzheimer's Disease
• Mini-Mental State Examination (MMSE) 20 to 26 at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 6 weeks

Exclusion criteria

• Previously participated in an AD vaccine study and received active treatment
• History or presence of an active autoimmune and/or with an acute or chronic inflammation, and/or clinically relevant atopic condition.
• History or presence of seizures and/or cerebrovascular disease.
• Presence of an other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

27 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Biological: CAD106

2

Placebo Comparator group

Treatment:

Biological: Placebo